ING235 ING235 Pill - blue capsule/oblong
Pill with imprint ING235 ING235 is Blue, Capsule/Oblong and has been identified as Mesalamine Extended-Release 0.375 g. It is supplied by Ingenus Pharmaceuticals, LLC.
Mesalamine is used in the treatment of Ulcerative Colitis, Maintenance; Ulcerative Colitis, Active; Crohn's Disease, Maintenance; Inflammatory Bowel Disease; Ulcerative Colitis and belongs to the drug class 5-aminosalicylates. excluding Asacol and Asacol HD: There is no proven risk in humans during pregnancy. Asacol and Asacol HD: Risk cannot be ruled out during pregnancy. Mesalamine 0.375 g is not a controlled substance under the Controlled Substances Act (CSA).
Images for ING235 ING235
Mesalamine Extended-Release
- Imprint
- ING235 ING235
- Strength
- 0.375 g
- Color
- Blue (blue opaque)
- Shape
- Capsule/Oblong (hard gelatin capsule)
- Availability
- Prescription only
- Drug Class
- 5-aminosalicylates
- Pregnancy Category
- B - No proven risk in humans - excluding Asacol and Asacol HD, C - Risk cannot be ruled out - Asacol and Asacol HD
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Ingenus Pharmaceuticals, LLC
- Manufacturer
- Novast Laboratories, Ltd.
- National Drug Code (NDC)
- 50742-0371
More about mesalamine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (426)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: 5-aminosalicylates
- Breastfeeding
Patient resources
- Mesalamine drug information
- Mesalamine rectal
- Mesalamine (Oral) (Advanced Reading)
- Mesalamine (Rectal) (Advanced Reading)
- Mesalamine Rectal Enema
- Mesalamine Suppositories
Other brands
Lialda, Apriso, Pentasa, Canasa, ... +4 more
Professional resources
- Mesalamine monograph
- Mesalamine (FDA)
- Mesalamine Capsules (FDA)
- Mesalamine Controlled-Release Capsules (FDA)
- Mesalamine Delayed Release Tablets (FDA)
Other brands
Lialda, Apriso, Pentasa, Asacol, ... +5 more
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.